Redigerer Favipiravir (avsnitt)

===Andre virussykdommer===
Favipiravir er blitt, eller blir, testet mot en rekke andre virussykdommer. Foruten mot ebola og covid-19, gjelder dette [[nipahvirus]], [[vestnilfeber]], [[gulfeber]]<nowiki/>virus, [[munn-og-klovsyke]]<nowiki/>virus, og en rekke andre [[flavivirus]]er, [[arenavirus]]er, [[bunyavirus]]et og [[alfavirus]]er.<ref name=Furuta>{{cite journal | vauthors = Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD | display-authors = 6 | title = T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections | journal = Antiviral Research | volume = 82 | issue = 3 | pages = 95–102 | date = Juni 2009 | pmid = 19428599 | pmc =  7127082| doi = 10.1016/j.antiviral.2009.02.198 }}</ref> Aktivitet mot [[enterovirus]]er<ref name=Furuta2013>{{cite journal | vauthors = Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL | title = Favipiravir (T-705), a novel viral RNA polymerase inhibitor | journal = Antiviral Research | volume = 100 | issue = 2 | pages = 446–54 | date = November 2013 | pmid = 24084488 | pmc = 3880838 | doi = 10.1016/j.antiviral.2013.09.015 }}</ref> og [[Rift Valley-feber]]<nowiki/>virus er også blitt påvist.<ref>{{cite journal | vauthors = Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS, Hartman AL | title = Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever | journal = PLOS Neglected Tropical Diseases | volume = 8 | issue = 4 | pages = e2790 | date = April 2014 | pmid = 24722586 | pmc = 3983105 | doi = 10.1371/journal.pntd.0002790 }}</ref> Favipiravir har vist begrenset effektivitet mot [[Zikavirus]] i dyrestudier, men da med mindre effekt en andre antivirale midler som for eksempel [[MK-608]].<ref>{{cite web | vauthors = Mumtaz N, van Kampen JJ, Reusken CB, Boucher CA, Koopmans MP | title = Zika Virus: Where Is the Treatment? | journal = Current Treatment Options in Infectious Diseases | volume = 8 | issue = 3 | pages = 208–211 | year = 2016 | pmid = 27547128 | pmc = 4969322 | doi = 10.1007/s40506-016-0083-7 }}</ref> Virkestoffet viste også noe effekt mot [[rabies]],<ref>{{cite journal | vauthors = Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A | title = Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis | journal = The Journal of Infectious Diseases | volume = 213 | issue = 8 | pages = 1253–61 | date = April 2016 | pmid = 26655300 | pmc = 4799667 | doi = 10.1093/infdis/jiv586 }}</ref> og er blitt benyttet eksperimentelt på noen mennesker smittet med det viruset.<ref>{{cite journal | vauthors = Murphy J, Sifri CD, Pruitt R, Hornberger M, Bonds D, Blanton J, Ellison J, Cagnina RE, Enfield KB, Shiferaw M, Gigante C, Condori E, Gruszynski K, Wallace RM | display-authors = 6 | title = Human Rabies - Virginia, 2017 | language = en-us | journal = MMWR. Morbidity and Mortality Weekly Report | volume = 67 | issue = 5152 | pages = 1410–1414 | date = Januar 2019 | pmid = 30605446 | pmc = 6334827 | doi = 10.15585/mmwr.mm675152a2 }}</ref>